What is Cardiology Update?

This one-day live virtual program will provide participants with practical and up-to-date information on the management of cardiac patients in the primary care setting.

This year's program will include a combination of presentations and opportunities for participants and faculty to interact.

Who should attend?

• Urban and Rural Primary Care Physicians

• Internists / ER Physicians

• Nursing Student, Nurses and Nurse Practitioners

• Allied Health Professionals

• Medical Students, Fellows and Residents

• Pharmacy Students / Pharmacists

Session 1

08:00 - 08:40 | Q&A 08:40 - 08:50

Out with the Old and In with the New!

Highlights from the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines

Glen Pearson, PharmD

Learning Objectives (1) Describe the evidence behind new therapy recommendations, including the REDUCE-IT trial, which showed a reduction in CV outcomes with icosapent ethyl in patients with elevated triglycerides. (2) Explain the role of new lipid parameters (Lp(a), non-HDL-C, and ApoB) and the new lipid thresholds for therapy intensification. (3) Review other practice-changing updates from the guidelines, including screening in all women with pregnancy complications and the role coronary artery calcium score as part of patient assessment.

Session 2

08:50 - 09:30 | Q&A 09:30 - 09:40

COVID-19 Myocarditis, Vaccine Related Myocarditis and Cardiac Implications of Post-COVID Syndrome | What you Need to Know

Ian Paterson, MD

Learning Objectives (1) Recognize myocarditis as a possible consequence of COVID-19 infection. (2) Review the diagnosis, workup, and management of patients with COVID-19 myocarditis.

Session 3

09:45 - 10:25 | Q&A 10:25 - 10:35

The Good, the Bad, and the Ugly

Everything You Need to Know About the Management of Heart Failure with Preserved Ejection Fraction (HFpEF).

Sheri Koshman, PharmD

Learning Objectives (1) Describe the results and implications of the EMPEROR-PRESERVED trial, which evaluated the effects of empagliflozin in HFpEF patients with and without diabetes. (2) Explain the evidence and role of other therapies investigated in HFpEF and how it applies to the management of HFpEF patients.

Session 4

10:35 - 11:15| Q&A 11:15- 11:25

Rate vs Rhythm Control in Atrial Fibrillation

What is the New Consensus?

Haran Yogasundaram, MD

Learning Objectives (1) Review the history of clinical trials regarding rate vs. rhythm control in non-valvular atrial fibrillation. (2) Describe the latest Canadian guidelines on atrial fibrillation and changes from the previous guidelines. (3) Outline ongoing and future trials that may inform rate vs. rhythm control in future practice.

Session 5

11:30 - 12:10 | Q&A 12:10 - 12:20

Approach to Assessing and Managing Chest Pain in Women

Michelle Graham, MD

Learning Objectives (1) List sex differences between men and women in the presentation of chest pain. (2) Describe the care gap between men and women for various cardiovascular conditions. (3) Outline differences in the management of men and women for various cardiovascular conditions. (4) Describe strategies to mitigate systemic biases such as ensuring adequate representation in clinical trial.

Session 6

12:20 - 13:00 | Q&A 13:00 - 13:10

To Kill Two Birds with One Stone? Therapies That Can Offer Both Cardiovascular and Renal Protection

Alexandra Saunders, MD

Learning Objectives (1) Explore the CV and Renal outcomes of newer medications, including SGLT-2 inhibitors, finerenone, and GLP-1 agonists. (2) Define the patient population that would benefit from these newer therapies and how it can be applied to practice.

Registration Sold Out

The 2022 program registration will only be available between April 1-25, 2022.

Professional Development

All attendees will receive a Certificate of Attendance confirming hours.